Effects of metformin on disease flares in patients with systemic lupus erythematosus: post hoc analyses from two randomised trials.

ABSTRACT:

Objective

To confirm that metformin prevents flares in patients with SLE with low disease activity, we performed a post hoc analysis combining our previous two randomised trials.

Methods

Post hoc analyses were performed on data from the open-labelled proof-of-concept trial (n=113, ChiCTR-TRC-12002419) and placebo-controlled 'Met Lupus' trial (n=140, NCT02741960) comparing the efficacy of metformin versus placebo/nil add-on to standard therapy in patients with SLE with low disease activity (SELENA-SLEDAI ≤4). The primary endpoint was defined by the SELENA-SLEDAI Flare Index at 12-month follow-up. A subgroup analysis was performed.

Results

Overall, 201 eligible patients were included, with 99 allocated to metformin group and 102 allocated to the placebo/nil group. By 12

SUBMITTER: Sun F 

PROVIDER: S-EPMC7583791 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature